Top Markets
#1 Akedo Akedo +64.36%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.34%
#4 Cross Cross +45.41%
#5 Black Phoenix Black Phoenix +34.24%
#6 Velvet Velvet +30.05%
#7 OVERTAKE OVERTAKE +26.38%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +14.75%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +14.03%
#10 Palladium Network Palladium Network +12.84%
Coin of the day
Akedo Akedo
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Lipidor AB (publ) Lipidor AB (publ)

Lipidor AB (publ)

LIPI
Rang in Aktien #39098
Lipidor AB (publ), a Swedish pharmaceutical company founded in Danderyd in... Lipidor AB (publ), a Swedish pharmaceutical company founded in Danderyd in 2009, specializes in developing medicinal products. Its core business centers on creating treatments for various skin conditions, including psoriasis, bacterial skin infections, and atopic dermatitis. The company's product pipeline includes AKP-01, which is currently in Phase III clinical trials for psoriasis, while other formulations like AKP-02 (also for psoriasis) and AKP-03 and AKP-07 (for eczema) are in earlier, preclinical development stages. Beyond its own drug candidates, Lipidor manufactures and supplies active pharmaceutical ingredients (APIs). These APIs are incorporated into products addressing a broad spectrum of therapeutic applications, such as managing psoriasis, microbial infections, inflammation, fungal issues, local pain relief, acne, wound healing, eczema, and migraines. Lipidor also caters to the animal health market, offering a line of spray-on skin care products for dogs, cats, and horses. Additionally, it develops consumer health items designed for purposes like antibacterial action, antiseptic care, moisturizing, disinfection, and treating acne and warts. In a key strategic alliance, Lipidor has partnered with Cannassure Therapeutics Ltd. This collaboration aims to advance topical medicinal cannabis products specifically formulated to alleviate skin inflammations and psoriatic lesions.
Aktienkurs
$0.02243487
Zuletzt synchronisiert: 2025-06-04
Marktkapitalisierung
$650.09K
Veränderung (1 Tag)
0.39%
Veränderung (1 Jahr)
0.00%
Land
SE
Handel Lipidor AB (publ) (LIPI)

Kategorie

Healthcare
Operative Marge für Lipidor AB (publ) (LIPI)
Operative Marge zum August 2026 TTM: -101,500.00%
Laut den neuesten Finanzberichten und dem Aktienkurs von Lipidor AB (publ) beträgt die aktuelle operative Marge (TTM) -101,500.00%. Am Ende des Jahres 2023 lag die operative Marge bei -19,812.82%.
Historie der operativen Marge von Lipidor AB (publ) von 2016 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) -101,500.00% 0.00%
2024 -101,500.00% 412.29%
2023 -19,812.82% -78.50%
2022 -92,155.56% 66,165.59%
2021 -139.07% -94.70%
2020 -2,623.23% -86.32%
2019 -19,177.78% 510.45%
2018 -3,141.56% 240.80%
2017 -921.82% -46.73%
2016 -1,730.46% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
45.87% -100.00%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
26.81% -100.00%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
27.60% -100.00%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
26.59% -100.00%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
27.59% -100.00%
US
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.